Enlivex Therapeutics Ltd.
ENLV | NASDAQ
$1.29
-$0.10 (-7.19%)
At close: Nov 5, 2026, 3:59 PM ET
$1.35
+$0.06 (+4.65%)
After-hours:
Nov 5, 2026, 5:16 PM ET
Company Profile
Enlivex Therapeutics Ltd., established in 2005 and based in Nes Ziona, Israel, operates as a clinical-stage biotechnology firm dedicated to macrophage reprogramming immunotherapy. The company is currently advancing Allocetra, its flagship cell-based therapeutic. This treatment is undergoing Phase II clinical evaluation for its effectiveness in addressing organ dysfunction and failure that arises from sepsis. Additionally, Allocetra is being investigated in preclinical studies for its potential application in solid tumor therapy.
Key Executives
| Name | Position |
|---|---|
| Oren Hershkovitz | Chief Executive Officer |
| Shachar Shlosberger | Chief Financial Officer |
| Veronique Amor-Baroukh | Chief Operating Officer |
| Dror Mevorach | Founder and Scientific Advisor |
| Einat Galamidi | Chief Medical Officer |
| Shai Novik | Executive Chairman |
| Sigal Arad | Director of Human Resources |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 02, 2026 | 6-K | Filing |
| Oct 28, 2026 | 6-K | Filing |
| Oct 27, 2026 | 6-K | Filing |
| Oct 22, 2026 | 6-K | Filing |
| Oct 19, 2026 | 6-K | Filing |
| Oct 02, 2026 | 6-K/A | [Amend] Filing |
| Oct 01, 2026 | 6-K/A | [Amend] Filing |
| Sep 29, 2026 | 6-K | Filing |
| Sep 25, 2026 | 6-K | Filing |
| Sep 22, 2026 | 6-K | Filing |
Enlivex Therapeutics Ltd.
| Country | Israel |
| IPO Date | Jul 31, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 34 |
| CEO | Oren Hershkovitz |
Contact Details
14 Einstein Street Ness Ziona,
TA 7403618 Israel
Stock Details
| Ticker Symbol | ENLV |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001596812 |
| CUSIP Number | |
| ISIN Number | IL0011319527 |
| SIC Code | 2834 |
Recent News
- 3 days ago / globenewswire.comEnlivex Announces Favorable 12-Month Topline Data from Phase I/IIa Allocetra Trial, Demonstrating Durable Treatment Response
- 9 days ago / globenewswire.comEnlivex Announces Randomization of 135 Patients in Phase 2b Trial of Allocetra in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- 10 days ago / globenewswire.comEnlivex Announces Receipt of Delisting Notice from Nasdaq; Intends to Appeal
- 14 days ago / globenewswire.comEnlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
- 18 days ago / globenewswire.comEnlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
- 1 month ago / globenewswire.comEnlivex Announces Termination of Previously-Announced Financing Payable in RAIN Tokens
- 2 months ago / zacks.comEnlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
- 3 months ago / globenewswire.comEnlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
- 3 months ago / globenewswire.comEnlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Add to Watchlist
Select watchlists to add or remove ENLV